Co-Diagnostics (CODX) Stock Price

Co-Diagnostics Price

NASDAQ·CLOSED
0.18
​
Market closed

Revenue has compounded at 51.2% per year over the past 10 years to 622,489.00 USD. Co-Diagnostics's net margin stands at -7,533.6%, down from 37.5% several years earlier.

Co-Diagnostics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics business model & stock analysis

Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment.

Frequently asked questions about Co-Diagnostics

7 analysts currently rate the Co-Diagnostics stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Co-Diagnostics to generate revenue of 654,000.00 USD and earnings per share of -2.36 USD.

Converted at the current exchange rate, the Co-Diagnostics share trades at 0.17 EUR (0.18 USD).

The Co-Diagnostics share (CODX) is listed on 6 stock exchanges, including: NASDAQ (CODX), London (0A50.L), Frankfurt (C97.F), München (C97.MU), Düsseldorf (C97.DU), Hamburg (C97.HM).

The expected revenue of Co-Diagnostics is 654,000.00 USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Co-Diagnostics is -3.13 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Co-Diagnostics is currently -0.08. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Co-Diagnostics stock.

The price-to-sales ratio (P/S) of Co-Diagnostics is currently 0.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Co-Diagnostics stock.

The Eulerpool Quality Score for Co-Diagnostics is 4/10.

The ISIN of Co-Diagnostics is US1897632048. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Co-Diagnostics is A2DU6V. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Co-Diagnostics is CODX. The ticker symbol is used to trade Co-Diagnostics shares on the stock exchange.

Fair ValueTerminal
0.15 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
5,412.95 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jul 12, 2017
ISIN
US1897632048
Cusip
189763105
Sedol
BD3BX23
Market capitalization
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.08
P/Ee 2027
-0.29
P/Ee 2028
-0.03
P/Ee 2029
0.03
P/Ee 2031
0.01
P/S
P/Se
0.37
EV/EBIT
0.33
P/B Ratio
0.01
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-214.48 %
Last updated Nov 19, 2026, 3:51 AM

Co-Diagnostics Ticker

DÜSSELDORF · C97.DUFRANKFURT · C97.FHAMBURG · C97.HMLONDON · 0A50.LMUNICH · C97.MUNASDAQ · CODX